Hydrocortisone Acetate

HYDROCORTISONE ACETATE- hydrocortisone acetate suppository
Central Texas Community Health Centers

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

DESCRIPTION

Each suppository for rectal administration contains 25 mg hydrocortisone acetate USP in a hydrogenated cocoglyceride base. Hydrocortisone acetate is a corticosteroid.

Chemically, hydrocortisone acetate is pregn-4-ene-3, 20 dione, 21- (acetyloxy)-11, 17-dihydroxy-, (11β)- with the following structural formula:

Chemical StructureChemical Structure

CLINICAL PHARMACOLOGY

In normal subjects, about 26 percent of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.

Topical steroids are primarily effective because of their anti-inflammatory, antipruritic and vasoconstrictive action.

Hydrocortisone Acetate Indications and Usage

For use in inflamed hemorrhoids, post irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.

CONTRAINDICATIONS

Hydrocortisone acetate suppositories are contraindicated in those patients with a history of hypersensitivity to any of the components.

PRECAUTIONS

Do not use unless adequate proctologic examination is made.

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

PREGNANCY CATEGORY C

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women.

It is not known whether this drug is excreted in human milk.

Until adequate studies in pregnant or lactating women have been conducted, this drug should be used during pregnancy or by nursing mothers only when clearly needed and when the potential benefits outweigh the potential risks.

ADVERSE REACTIONS

The following local adverse reactions have been reported with corticosteroid suppositories:

1.
Burning
2.
Itching
3.
Irritation
4.
Dryness
5.
Folliculitis
6.
Hypopigmentation
7.
Allergic Contact Dermatitis
8.
Secondary Infection

DRUG ABUSE AND DEPENDENCE

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

OVERDOSAGE

If signs and symptoms of systemic overdosage occur, discontinue use.

DOSAGE AND ADMINISTRATION

Usual dosage:

One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

HOW SUPPLIED

Hydrocortisone acetate suppositories are easy to open, color coded and available in cartons of:

12’s NDC 76413-132-12

Store at controlled room temperature 15° to 30°C (59° to 86°F). Protect from freezing.

Manufactured By
Perrigo ®
Minneapolis, MN 55427
(01-12)

PRINCIPAL DISPLAY PANEL — 12 Packet Box Label

CommUnityCare Federally Qualified Health Centers

HYDROCORTISONE
SUPP.25MG # 12

Date:

Name:
Dr.

USE AS DIRECTED BY DOCTOR.

123456

1/1/01

Hydrocortisone Supp. 25 mg #12 NDC 76413-132-12

Batch: 123456
Lot: 123456
Exp: 1/1/01
PERRIGO

Federal law prohibits the transfer of this drug to any other person than the patient for whom prescribed.

PRINCIPAL DISPLAY PANEL -- 12 Packet Box Label
(click image for full-size original)
HYDROCORTISONE ACETATE
hydrocortisone acetate suppository
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:76413-132(NDC:0574-7090)
Route of Administration RECTAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDROCORTISONE ACETATE (HYDROCORTISONE) HYDROCORTISONE ACETATE 25 mg
Product Characteristics
Color WHITE Score no score
Shape BULLET Size 35mm
Flavor Imprint Code
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:76413-132-12 12 PACKET in 1 BOX contains a PACKET
1 1 SUPPOSITORY in 1 PACKET This package is contained within the BOX (76413-132-12)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 07/01/1990
Labeler — Central Texas Community Health Centers (079674019)
Establishment
Name Address ID/FEI Operations
Central Texas Community Health Centers 079674019 REPACK (76413-132), RELABEL (76413-132)

Revised: 04/2016 Central Texas Community Health Centers

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.